Edition:
United States

Profile: Vexim SA (ALVXM.PA)

ALVXM.PA on Paris Stock Exchange

20.01EUR
14 Dec 2017
Change (% chg)

€-0.08 (-0.40%)
Prev Close
€20.09
Open
€20.10
Day's High
€20.10
Day's Low
€19.54
Volume
18,464
Avg. Vol
41,292
52-wk High
€20.15
52-wk Low
€9.06

Vexim SA is a France-based company engaged in the medical sector. It develops invasive medical instruments used in preventing and treating vertebral fractures. The Company markets its flagship product, SpineJack, in Germany, the United Kingdom, Austria and Ireland under a agreement with Stryker Corp, in France via its own sales force and further distributers in Spain, Portugal, Italy, Turkey, Argentina and South Africa. SpineJack is a titanium implant which is inserted into the patient's vertebra via a transpedicular, minimally invasive approach. Furthermore, the Company's product portfolio includes Cohesion, a PolyMethyl MethAcrylat (PMMA) bone cement and a three-dimensional (3D) mapping software for combining images from Computerized Tomography (CT) scans into a 3D model. The Company operates through VEXIM and a technological system in the injection of orthopedic cement for its development in vertebroplasty. The Company is a subsidiary of Stryker Corporation.

Company Address

Vexim SA

75 rue Saint Jean
BALMA     31130
P: +335.61488663
F: +335.61489519

Company Web Links